In contrast, EGFR and HER3 positivity rate did not differ between primary tumours and liver metastasis ranging from 25 to 30% in gastric cancer patients, indicating selective overexpression of HER2 in metastatic liver tumours. Here, ERBB3 is linked to gastric cancer.